Earlier today, the Senate Judiciary Committee held an Executive Business Meeting in which the Committee discussed and favorably reported four bills aimed at reducing prescription drug prices for consumers and curbing perceived abuses of the patent system by brand pharmaceutical companies. The bills would do so by increasing the Federal Trade Commission’s (FTC’s) authority to initiate enforcement actions against drug companies. Senator Dick Durbin (D-IL), Chair of the Senate Judiciary Committee, opened the meeting with an explanation of the need for the bills. He said that nearly 40% of U.S. patients struggle to pay for medication. The world’s best-selling drug, Humira, brought in $16 billion in sales in 2019 and Humira manufacturer, AbbVie, has obtained 130 patents on the drug, with 90% filed after Food and Drug Administration (FDA) approval.
Recent Posts
- Why IP Rights Expire and Why They Must Be Strong While They Last
- Potential Shifts in Section 337 Precedent: What The Data Tells Us
- Back When the Supreme Court Got It Right On IP: Kewanee, 50 Years Later
- Other Barks and Bites for Friday, May 10: Bipartisan Congress Members Call for GAO Study on March-In Proposal; USPTO Warns Trademark Applicants of Data Leak; Supreme Court Rejects Time Limit on Copyright Damages
- The World’s AI Companies Are Killing Trust in the Technology